coenzyme-q10 and Deafness

coenzyme-q10 has been researched along with Deafness* in 6 studies

Reviews

1 review(s) available for coenzyme-q10 and Deafness

ArticleYear
[Mitochondrial diabetes mellitus].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, Sep-28, Volume: Suppl 3

    Topics: Coenzymes; Deafness; Diabetes Mellitus, Type 2; Diagnosis, Differential; DNA, Mitochondrial; Hypoglycemic Agents; Insulin; Insulin Secretion; MELAS Syndrome; Mitochondria; Mutation; Prognosis; Ubiquinone

2006

Trials

1 trial(s) available for coenzyme-q10 and Deafness

ArticleYear
The effects of coenzyme Q10 treatment on maternally inherited diabetes mellitus and deafness, and mitochondrial DNA 3243 (A to G) mutation.
    Diabetologia, 1998, Volume: 41, Issue:5

    The characteristic clinical features of diabetes mellitus with mitochondrial DNA (mtDNA) 3243(A-G) mutation are progressive insulin secretory defect, neurosensory deafness and maternal inheritance, referred to as maternally inherited diabetes mellitus and deafness (MIDD). A treatment for MIDD to improve insulin secretory defects and reduce deafness has not been established. The effects of coenzyme Q10 (CoQ10) treatment on insulin secretory response, hearing capacity and clinical symptoms of MIDD were investigated. 28 MIDD patients (CoQ10-DM), 7 mutant subjects with impaired glucose tolerance (IGT), and 15 mutant subjects with normal glucose tolerance (NGT) were treated daily with oral administration of 150 mg of CoQ10 for 3 years. Insulin secretory response, blood lactate after exercise, hearing capacity and other laboratory examinations were investigated every year. In the same way we evaluated 16 MIDD patients (control-DM), 5 mutant IGT and 5 mutant NGT subjects in yearly examinations. The insulin secretory response assessed by glucagon-induced C-peptide secretion and 24 h urinary C-peptide excretion after 3 years in the CoQ10-DM group was significantly higher than that in the control-DM group. CoQ10 therapy prevented progressive hearing loss and improved blood lactate after exercise in the MIDD patients. CoQ10 treatment did not affect the diabetic complications or other clinical symptoms of MIDD patients. CoQ10 treatment did not affect the insulin secretory capacity of the mutant IGT and NGT subjects. There were no side effects during therapy. This is the first report demonstrating the therapeutic usefulness of CoQ10 on MIDD.

    Topics: Adult; C-Peptide; Coenzymes; Deafness; Diabetes Complications; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; DNA, Mitochondrial; Family Health; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Hearing; Humans; Lactic Acid; Male; Middle Aged; Mothers; Point Mutation; Time Factors; Treatment Outcome; Ubiquinone

1998

Other Studies

4 other study(ies) available for coenzyme-q10 and Deafness

ArticleYear
Effects of CoQ10 Replacement Therapy on the Audiological Characteristics of Pediatric Patients with
    BioMed research international, 2022, Volume: 2022

    Primary coenzyme Q10 (CoQ10) deficiency refers to a group of mitochondrial cytopathies caused by genetic defects in CoQ10 biosynthesis. Primary coenzyme Q10 deficiency-6 (COQ10D6) is an autosomal recessive disorder attributable to biallelic

    Topics: Ataxia; Deafness; Hearing Loss, Sensorineural; Humans; Mitochondrial Diseases; Muscle Weakness; Nephrotic Syndrome; Steroids; Ubiquinone

2022
Unusual occurrence of intestinal pseudo obstruction in a patient with maternally inherited diabetes and deafness (MIDD) and favorable outcome with coenzyme Q10.
    Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:8

    Maternally inherited diabetes and deafness (MIDD) has been related to an A to G transition in the mitochondrial tRNA Leu (UUR) gene at the base pair 3243. This subtype of diabetes is characterized by maternal transmission, young age at onset and bilateral hearing impairment. Besides diabetes and deafness, the main diagnostic features, a wide range of multisystemic symptoms may be associated with the A3243G mutation. Organs that are most metabolically active, such as muscles, myocardium, retina, cochlea, kidney and brain are frequently affected. Gastrointestinal tract symptoms are also common in patients with mitochondrial disease and constipation and diarrhea are the most frequent manifestations. However, there are few prior reports of intestinal pseudo obstruction in MIDD patients. Here we report the case of a patient with MIDD associated with the mtDNA A3243G mutation who developed chronic intestinal pseudo obstruction, and the introduction of Coenzyme Q10 as adjunctive therapy led to a solution of the pseudo obstruction.

    Topics: Deafness; Diabetes Complications; Diabetes Mellitus; DNA, Mitochondrial; Female; Humans; Intestinal Pseudo-Obstruction; Middle Aged; Pedigree; Point Mutation; Ubiquinone; Vitamins

2008
Beware the thin, deaf 'type 2' diabetic: maternally inherited diabetes and deafness with systemic (mitochondrial) manifestations.
    Internal medicine journal, 2004, Volume: 34, Issue:8

    Topics: Aged; Antioxidants; Coenzymes; Deafness; Diabetes Mellitus, Type 2; DNA Mutational Analysis; DNA, Mitochondrial; Female; Humans; Mitochondrial Diseases; Phenotype; Point Mutation; Ubiquinone

2004
Could coenzyme Q10 and L-carnitine be a treatment for diabetes secondary to 3243 mutation of mtDNA?
    Diabetologia, 1995, Volume: 38, Issue:12

    Topics: Blood Glucose; C-Peptide; Carnitine; Coenzymes; Deafness; Diabetes Mellitus, Type 2; DNA, Mitochondrial; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Insulin; Magnetic Resonance Spectroscopy; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Point Mutation; Retinitis; RNA, Transfer, Leu; Ubiquinone

1995